Aortic Calcification and Central Blood Pressure in Patients With Chronic Kidney Disease

NCT ID: NCT04114695

Last Updated: 2022-03-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

185 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-10-15

Study Completion Date

2022-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Aim and background:

This study will seek to identify physiological and biochemical factors explaining and predicting a higher than expected central (aortic) blood pressure (BP) in patients with chronic kidney disease (CKD). The basic hypothesis of the study is that the degree of aortic calcification is an important component of elevated central BP, which, in turn, is important for the organ-damage and increased risk of cardiovascular disease associated with CKD.

Methods:

Adult patients with varying degrees of CKD undergoing scheduled coronary angiography (CAG) at Aarhus University Hospital will be included in this study.

During the CAG procedure, systolic and diastolic BP is determined in the ascending part of aorta by a calibrated pressure transducer connected to the fluid-filled CAG catheter.

Simultaneous with the registration of invasive aortic BP, estimation of central BP is performed using radial artery tonometry (SphygmoCor®), while a corresponding brachial BP is also measured.

Prior to the CAG, a non-contrast CT scan of aorta in its entirety will be performed to enable blinded quantification of calcification in the wall of aorta and coronary arteries.

Furthermore, echocardiography, resting BP measurement and a range of blood- and urine samples will be performed.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arterial Calcification Kidney Diseases Coronary Artery Disease Aortic Calcification Stroke Vascular Diseases Vascular Calcification

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Non-CKD (eGFR >60 ml/min/1.73 m2)

Patients with renal function considered normal for age (eGFR \>60 ml/min/1.73 m2) without proteinuria or structural kidney disease.

No interventions assigned to this group

CKD stage 3a (eGFR 45-59 ml/min/1,73 m2)

Patients with CKD stage 3a (eGFR 45-59 ml/min/1,73 m2)

No interventions assigned to this group

CKD stage 3b (eGFR 30-44 ml/min/1,73 m2)

Patients with CKD stage 3b (eGFR 30-44 ml/min/1,73 m2)

No interventions assigned to this group

CKD stage 4 (eGFR 15-29 ml/min/1,73 m2)

Patients with CKD stage 4 (eGFR 15-29 ml/min/1,73 m2)

No interventions assigned to this group

CKD stage 5 (eGFR <15 ml/min/1,73 m2)

Patients with CKD stage 5 (eGFR \<15 ml/min/1,73 m2). 50% of these patients will be in dialysis, while the other 50% will be pre-dialysis patients.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>18 years
* Patient referred for planned CAG at the Department of Cardiology, Aarhus University Hospital (AUH)
* eGFR constantly either \>60 ml/min or \<60 ml/min in at least 2 separate blood-sample measurements over at least 3 months.
* Signed informed consent-form.

Exclusion Criteria

* Antihypertensive treatment changed within the last two weeks prior to the CAG.
* Severe aortic valve stenosis (\<1 cm) as central hemodynamics may be altered
* Maximum number of patients in CKD-group already reached.
* Atrial fibrillation or other cardiac arrhythmia making radial Pulse Wave Analysis (PWA) estimations impossible.
* Known significant stenosis of a. subclavia or a. brachialis
* Bilateral arteriovenous-fistula (even if one or both of these have been surgically removed) as this may significantly affect the pulse-wave form.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Central Jutland Regional Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jakob Tobias Nyvad

M.D., PhD-student

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Niels H Buus, MD PhD DMSc

Role: STUDY_CHAIR

Department of Renal diseases, Aarhus University Hospital

Jakob T Nyvad, M.D.

Role: PRINCIPAL_INVESTIGATOR

The Clinic of Hypertension, Aarhus University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Aarhus University Hospital

Aarhus, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

References

Explore related publications, articles, or registry entries linked to this study.

Nyvad J, Christensen KL, Andersen G, Reinhard M, Norgaard BL, Madsen JS, Nielsen S, Thomsen MB, Jensen JM, Peters CD, Buus NH. PIVKA-II but not dp-ucMGP is associated with aortic calcification in chronic kidney disease. BMC Nephrol. 2024 Nov 27;25(1):426. doi: 10.1186/s12882-024-03876-5.

Reference Type DERIVED
PMID: 39604863 (View on PubMed)

Nyvad J, Christensen KL, Andersen G, Reinhard M, Maeng M, Nielsen S, Thomsen MB, Jensen JM, Norgaard BL, Buus NH. Aortic Calcification is Associated With the Difference Between Invasive Central and Cuff-Measured Brachial Blood Pressure in Chronic Kidney Disease. Am J Hypertens. 2024 Jun 14;37(7):455-464. doi: 10.1093/ajh/hpae029.

Reference Type DERIVED
PMID: 38477704 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VEK-nr 66842

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Kidney Disease Biomarkers
NCT00255398 COMPLETED
The CPH-MBD Cohort
NCT07193056 NOT_YET_RECRUITING
CKD Cachexia and Gut Microbiome
NCT06986265 RECRUITING